Indaptus Therapeutics is trading 5.18% higher at $3.32 on October 26, 2026, with no specific catalyst identified. - The recently reported $24 million private placement was completed earlier and does not establish a direct catalyst for this session. - Major indexes are higher, which may be supportive, but available evidence does not confirm this caused the stock’s gain.